News

Stella Opens Flagship PTSD Treatment Location in Chicago and Secures $7M in Funding

Funds raised from Sterling Partners will be used to further innovative research and expand access to cutting-edge careCHICAGO, May 09,…

2 years ago

Stereotaxis Reports 2023 First Quarter Financial Results

ST. LOUIS, May 09, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for…

2 years ago

Interim Results of Study That Used Non-invasive Wireless Patches to Monitor Myoelectric Activity of Crohn’s Disease Patients in Flare and Remission

MOUNTAIN VIEW, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with…

2 years ago

AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast

OCALA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company…

2 years ago

Cerevance Announces Presentation at Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel…

2 years ago

Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome

- Children in the ELPIS I trial had 100% survival up to 5 years of age after receiving Lomecel-BTM compared…

2 years ago

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within the Sports and Spine Clinic in Oregon

Follows successful evaluation by Dr. Jimmy D. Huebert, MD, including Epidural Steroid Injection (ESI) procedures in lumbar, thoracic and cervical…

2 years ago

SeqLL Provides First Quarter 2023 Financial Results

BILLERICA, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company…

2 years ago

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

- Upcoming clinical and regulatory milestones remain on track with previous guidance – - Current cash, cash equivalents and short-term…

2 years ago

SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform

-  FDA has approved five of seven sections in a rolling submission required for a New Animal Drug Application (NADA)…

2 years ago